Skip to main content
. 2021 May 5;87(11):4386–4396. doi: 10.1111/bcp.14860

TABLE 3.

Base‐case results of the cost‐effectiveness analysis

SoC Remdesivir Incremental
Total costs (CN¥) 2 255 649 459 2 353 580 729 97 931 270
QALDs during the analytic period (QALY equivalent) 512 651 191 (1 403 562) 512 677 159 (1 403 634) 25 968 (71)
QALY loss due to death 34 026 27 150 6875
QALY NA NA 6947
ICER (CN¥/QALY) NA NA 14 098

SoC, standard of care; QALD, quality‐adjusted life day; QALY, quality‐adjusted life year; ICER, incremental cost‐effectiveness ratio.